Feasibility & proof-of-concept
Can the route work, at what scale, and what does it cost to find out? We scope the question, run the work, and report the answer with the assumptions stated.
R&D Projects · proof-of-concept
Complex R&D, managed to a decision.
Brick 42 runs proof-of-concept R&D to support strategic portfolio decisions — conjugates, novel vectors, proteins and oligonucleotides — from feasibility through to a partner-ready package.
What we take on
Early work, structured to a go/no-go.
The value of an R&D project is the decision it settles, so each one is scoped against a decision rather than a deliverable in the abstract.
Conjugates & novel vectors
Linker chemistry, targeting and delivery formats where the generic route does not yet exist. Early work, carried only as far as the evidence supports.
Proteins & oligonucleotides
The complex modalities behind the pipeline: synthesis, analytics, and the development path to a transferable process.
How a project runs
Four stages. One answer each.
Every stage ends with a decision the portfolio can act on — proceed, hold, or stop — not a status report.
- ScopeDefine the decision the work must serve, and the evidence that settles it.
- FeasibilityRoute, scale and cost assessed against that decision, not in the abstract.
- Proof-of-conceptThe critical step demonstrated; assumptions, yields and risks recorded.
- HandoverA partner-ready package: process, analytics, documentation and the open questions.
At each gateWhat you get
| Recommendation | first, in one line |
| Evidence | source, date, confidence |
| Assumptions | stated, not buried |
| Next gate | the decision that follows |
The same discipline the Decision Support tool applies to a molecule, applied to a project.
Evidence
Funded work, real partners.
Our R&D is not theoretical. It sits inside funded programmes and an active joint venture — the collaborations behind the pipeline and the route to new molecules.
TRANSBORO
An Interreg VI-A Italy–Switzerland (2021–2027) project in Boron Neutron Capture Therapy, with Exeris Bio SA, the University of Eastern Piedmont and the University of Pavia.
exerisbio SA
A joint venture with Exeris SA — combining process development and scale-up capability with a shared route to complex molecules.
Protein research
An investment in protein research behind the pipeline — expanding the modalities Brick 42 can develop and transfer.
Next
Bring us the project, or just the question.
Tell us the modality and the decision it has to serve. If a molecule is the immediate issue, the Gate Brief gives you a first answer without a meeting.